Table 1 |
||
|
Patient characteristics |
||
|
BP Dataset |
TC Dataset |
|
|
n (%) or mean ± SD |
n (%) or mean ± SD |
|
|
|
||
|
Number of patients |
991 |
956 |
|
Female |
879 (88.7%) |
849 (88.8%) |
|
Race |
||
|
Caucasian |
70% |
70% |
|
Black |
11% |
11% |
|
Asian |
11% |
11% |
|
Other |
8% |
8% |
|
CAD events |
||
|
MI Angina |
25 75 |
20 71 |
|
Sudden cardiac death |
2 |
2 |
|
Total |
94 |
86 |
|
Agea |
||
|
At diagnosis |
31.0 ± 13.8 |
30.9 ± 13.8 |
|
At study entry |
37.1 ± 14.0 |
37.5 ± 14.1 |
|
Disease durationa |
||
|
At first clinic visit |
4.0 ± 5.8 |
4.0 ± 5.9 |
|
At study entry |
6.1 ± 7.9 |
6.6 ± 8.1 |
|
SLEDAI-2Kb |
||
|
At first clinic visit |
9.7 ± 7.7 |
9.6 ± 7.7 |
|
At study entry |
9.2 ± 7.5 |
8.3 ± 7.2 |
|
SLICC/ACR-DIc |
||
|
At first clinic visit |
0.3 ± 0.7 |
0.3 ± 0.7 |
|
At study entry |
0.5 ± 1.2 |
0.6 ± 1.2 |
|
Steroids at study entry |
623 (63%) |
625 (65.6%) |
|
Antimalarials at study entryd |
380 (38.5%) |
385 (40.4%) |
|
Immunosuppressivese |
||
|
At study entry |
235 (23.8%) |
233 (24.5%) |
|
Hypertension at study entryf |
221 (22.3%) |
212 (22.6%) |
|
Hypercholesterolemia at study entryg |
344 (41.8%) |
408 (42.7%) |
|
Diabetes at study entryh |
28 (2.9%) |
31 (3.3%) |
|
Smoker at study entryi |
190 (19.5%) |
183 (19.5%) |
|
Antihypertensive use |
||
|
at study entryj |
174/691 (25.2%) |
174/699 (24.9%) |
|
Lipid-lowering meds |
||
|
at study entryk |
23/440 (5.2%) |
22/440 (5.0%) |
|
|
||
|
BP, blood pressure (mm Hg); CAD, coronary artery disease; MI, myocardial infarction; SD, standard deviation; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; TC, total plasma cholesterol (mmol/L). aYears. bScores range from 0 to 105, with higher scores indicating more-active disease. cScores range from 0 to 46, with higher scores indicating greater disease-related damage. dAntimalarials include chloroquine and hydroxychloroquine. eImmunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide. fDiastolic BP ≥90 or systolic BP ≥140 mm Hg or treatment with antihypertensive medication. gHypercholesterolemia was defined as cholesterol > 5.2 mmol/L or lipid-lowering therapy. hDiabetes was defined as fasting plasma glucose > 7.0 mmol/L or diabetes therapy. iCurrent smoking is defined as smoking an average of one or more cigarettes per day over the past month. jAll classes of antihypertensives including diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin type II receptor blockers. kHMG Co-A reductase inhibitors (statins) |
||
|
Nikpour et al. Arthritis Research & Therapy 2011 13:R156 doi:10.1186/ar3473 |
||
